Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 26947331

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2016 Apr
First author
Cristofanilli M

This record carries publication-notice metadata. Review the notices below before relying on it.

Publication notices

absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Apr;17(4):402-403. doi: 10.1016/S1470-2045(16)00144-3.
    note
    Source null
    related pmid
    26947329
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Apr;17(4):e136. doi: 10.1016/S1470-2045(16)00155-8.
    note
    Source null
    related pmid
    27300673
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2016 Jul;17(7):e270. doi: 10.1016/S1470-2045(16)30222-4.
    note
    Source null
    related pmid
    27733295
    relationship
    Erratum in

Authors and identifiers

  1. name
    Cristofanilli M
    type
    Author
  2. name
    Turner NC
    type
    Author
  3. name
    Bondarenko I
    type
    Author
  4. name
    Ro J
    type
    Author
  5. name
    Im SA
    type
    Author
  6. name
    Masuda N
    type
    Author
  7. name
    Colleoni M
    type
    Author
  8. name
    DeMichele A
    type
    Author
  9. name
    Loi S
    type
    Author
  10. name
    Verma S
    type
    Author
  11. name
    Iwata H
    type
    Author
  12. name
    Harbeck N
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Cristofanilli M
    type
    Author
  2. name
    Turner NC
    type
    Author
  3. name
    Bondarenko I
    type
    Author
  4. name
    Ro J
    type
    Author
  5. name
    Im SA
    type
    Author
  6. name
    Masuda N
    type
    Author
  7. name
    Colleoni M
    type
    Author
  8. name
    DeMichele A
    type
    Author
  9. name
    Loi S
    type
    Author
  10. name
    Verma S
    type
    Author
  11. name
    Iwata H
    type
    Author
  12. name
    Harbeck N
    type
    Author
bibliography ids
  1. nci-bib-b487d82c5900dc396735476c
book metadata
content sha256
14754714463333cc567bed2e5c053411998c343e6291947bfbd079442c41d8b2
document type
citation
dois
  1. 10.1016/S1470-2045(15)00613-0
electronic publication date
display
2016 Mar 3
precision
day
year
2016
evidence scope
bibliographic_metadata_only
id
pubmed:26947331
immutable id
pubmed:26947331@14754714463333cc567bed2e5c053411998c343e6291947bfbd079442c41d8b2
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
4
name
The Lancet. Oncology
nlm unique id
100957246
pages
425-439
volume
17
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
true
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2016 Apr;17(4):402-403. doi: 10.1016/S1470-2045(16)00144-3.
    note
    Source null
    related pmid
    26947329
    relationship
    Comment in
  2. citation
    Lancet Oncol. 2016 Apr;17(4):e136. doi: 10.1016/S1470-2045(16)00155-8.
    note
    Source null
    related pmid
    27300673
    relationship
    Erratum in
  3. citation
    Lancet Oncol. 2016 Jul;17(7):e270. doi: 10.1016/S1470-2045(16)30222-4.
    note
    Source null
    related pmid
    27733295
    relationship
    Erratum in
outcomes validated
false
pmid
26947331
provenance
batch id
fe5a46c92522c34737e8
provider
NCBI PubMed ESummary
record sha256
bf208dae3b3d26dd39d7935b7105f651585bc4a1f1d92921db79c9bf10bb30d3
response sha256
2c7bacd02d2ece3813daf1a0f92260c22884bd9268942fcca2088ab229bfb4d1
retrieved at
2026-09-09T23:47:17.939307+00:00
publication date
display
2016 Apr
precision
month
year
2016
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Multicenter Study
  4. Randomized Controlled Trial
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/26947331/
title
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial.

Preserved source evidence · Not medical advice